A Test in Context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies

This JACC “Test in Context” review is, for many clinicians, the definitive primer on lipoprotein(a) — written by the researcher most associated with both its measurement and its emerging therapies.

Tsimikas synthesizes the full picture: Lp(a) is genetically determined, independent of and additive to LDL, and a likely causal driver of both atherosclerotic disease and calcific aortic valve stenosis — a risk that persists even when LDL is well controlled. Crucially, he connects the biology (oxidized phospholipids carried on Lp(a)) to the coming wave of RNA-targeted antisense therapies that would finally let the field test whether lowering Lp(a) lowers events.

The practical takeaway is to measure Lp(a) in patients with premature cardiovascular disease, a strong family history, or residual risk despite controlled LDL. The resistance is the longstanding “why test if you can’t treat it” fatalism that emerging therapies are dissolving.

We rate the evidence solid: a comprehensive, 78-reference synthesis in a leading journal. The author discloses significant conflicts (employment and patents with Ionis, an Lp(a)-drug developer) — transparently, but worth weighing. Its clinical significance is high — it educated a generation of clinicians on an underrecognized risk factor, arriving just as treatment became conceivable.